Brief: Coya’s COYA 303 Shows Promising CNS Anti-Inflammatory Effects & Treg-Boosting Effects in Preclinical Inflammation Model
16/09/2025 13:55
Sept 16 (Reuters) - Coya Therapeutics Inc COYA.O: COYA THERAPEUTICS' COYA 303 SHOWS PROMISING CENTRAL NERVOUS SYSTEM (CNS) ANTI-INFLAMMATORY EFFECTS AND SYSTEMIC REGULATORY T CELL (TREG) ENHANCING EFFECTS IN A PRECLINICAL ANIMAL INFLAMMATION MODEL Source text: ID:nPn4WRHSqa Further company coverage: COYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)